SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sirna Therapeutics Inc -- Ignore unavailable to you. Want to Upgrade?


To: bob zagorin who wrote (262)10/15/1999 12:32:00 PM
From: bob zagorin  Read Replies (1) | Respond to of 562
 
from Biospace.

New Exclusive Feature From BioSpace Decoder:

German Biotechnology -- Atugen: A Leading Light

Atugen was founded amid great fanfare in 1998 as a spinoff
from the Boulder-based Ribozyme Pharmaceuticals Inc. (RPI).
The reason for the fanfare was the money: the company
assembled a package of approximately $20 million (DM 36
million) in its first round of financing, a rousing start
in any country. In addition, the company was touted by
Rüttgers at the 1998 Biotechnology Industry Organization
conference in New York as a leading light of German biotech.

biospace.com